Goldline Pharmaceutical opened lower at ₹30.11, compared with its previous close of ₹30.51. In the last trading session on 12 Nov 2026, the stock traded between ₹29.83 and ₹30.91, with an average traded price of ₹30.43. It showed an upward intraday trend.
Return calculator
Time Period
An investment of ₹10,000 made 1 year ago in Goldline Pharmaceutical is now worth
₹ 5,445.00
Resulting in a loss of
₹ 4,555.00 (45.55%)
Invest now
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+0.40 (+1.31%)
Day High
₹30.91
Day Low
₹29.83
Day Open
₹30.11
Prev Close
₹30.51
Volume
21,000
Value Traded
₹0.06 Cr
1W Return
0.07%
1M Return
-4.89%
3M Return
-23.68%
6M Return
-45.55%
1Y Return
-45.55%
Fundamentals
Market Cap (₹ Cr.)
30
PE Ratio
-
PB Ratio
1.22
Dividend Yield
-
ROE
28.89%
ROCE
39.98%
Book Value (₹)
25.05
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
Investment Returns
1 Week
0.07%
6 Weeks
-
1 Month
-4.89%
3 Months
-23.68%
9 Months
-45.55%
Financials
Yearly
All values in ₹ crores
No data available.
Share Holding Pattern
Promoter59.54%
FII0.31%
DII0.09%
Retails & Others34.32%
Updates
2Sep
Goldline Pharmaceutical promoter raises stake to 29.27% with open market buy
Promoter Amol Laxmikant Mujumdar acquired 60,000 shares via open market. Stake increased by 0.62% to reach 29.27% of paid-up capital. Total issued share capital remains unchanged at 9.6 million shares. No encumbrances or pledges reported on the promoter's holdings.
2mo ago
2Sep
Goldline Pharmaceutical promoter acquires 18,000 shares via open market
Promoter Amol Laxmikant Mujumdar acquired 18,000 shares via open market purchase on September 1, 2026. His stake in Goldline Pharmaceutical rose from 29.27% to 29.46%. Total shareholding now stands at 2,827,988 equity shares. No shares are encumbered or pledged post-acquisition.
2mo ago
31Aug
Goldline Pharma shareholders approve director loans, related-party deals
All 8 resolutions passed with 100% support from voting members. Total valid votes cast: 5,866,994 shares (61.11% turnout). Shareholders approved RPTs with Activista, Nucleage, and Numerius. Unsecured loans from directors with equity conversion option authorized.
2mo ago
29Aug
Goldline Pharma net profit jumps 45% to ₹411.71 lakhs in FY26
Net profit surged 45% YoY to ₹411.71 lakhs in FY26. Revenue from operations and other income rose 11% to ₹3,119.88 lakhs. EPS improved to ₹5.97 from ₹4.11 in the previous year. Dividend of ₹12 per preference share declared for FY26. First AGM held after listing on BSE SME Platform in May 2026.
Swapan Khandelwal acquired 78,000 equity shares via open market on August 28, 2026. Promoter stake increases to 30.08% from 29.27%. Total holding now stands at 2,887,988 shares. No encumbrances on the acquired or existing shares.
2mo ago
7Aug
Goldline Pharmaceutical schedules 22nd AGM for August 29, 2026
Goldline Pharmaceutical Limited will hold its 22nd AGM on August 29, 2026, in Nagpur. Remote e-voting is available from August 25 to August 28, 2026, via Bigshare Services. The record date for voting eligibility is August 22, 2026, and the share transfer books will be closed from August 23 to August 29, 2026.
3mo ago
Similar Stocks
No similar stocks data available.
Return calculator
Time Period
An investment of ₹10,000 made 1 year ago in Goldline Pharmaceutical is now worth
₹ 5,445.00
Resulting in a loss of
₹ 4,555.00 (45.55%)
Invest now
Note: Past profits do not guarantee future returns.
